Categories
Blog News

Health Canada’s New Nicotine Rules: What’s Changing in 2024

Nicotine pouches in a round container on a wooden surface.

If you’re in the business of nicotine products like pouches, gums, patches, sprays, or lozenges (collectively known as nicotine replacement therapies, or NRTs), you need to know about Health Canada’s new nicotine rules. Major regulatory changes are now in place to ensure NRT products are marketed responsibly, labeled clearly, and sold in ways that prioritize consumer safety.

These new regulations introduce tighter advertising restrictions, comprehensive labeling requirements, and significant limits on where and how nicotine pouches can be sold. So, what do these changes mean for your business?

Whether you’re a manufacturer, supplier, or marketer, they could impact your products, packaging, and promotions. Keep reading to learn what’s changing, how it affects your operations, and how you can stay ahead. 

What’s Changing and Why It Matters

Health Canada’s new regulations are reshaping the nicotine industry, particularly for products like NRTs. These changes intend to tackle growing concerns about youth access and ensure consumers have accurate, transparent information. Here’s a closer look at the updates and their impact on your business:

Clearer Labeling Standards 

All nicotine products must now display nicotine content in milligrams. This gives consumers a clear understanding of product strength, helping them make better choices. Labels also require bold health warnings about addiction risks to ensure safety information is easy to spot. 

For businesses, this is an opportunity to strengthen customer trust. Transparent labelling shows accountability and can help your product stand out in a competitive market. 

Stricter Advertising Guidelines 

Marketing campaigns must focus on adult smokers looking for smoking cessation tools. Claims like “helps reduce cravings” now require solid evidence to back them up. Additionally, anything that could appeal to youth or non-smokers, like colourful imagery or playful language, is strictly prohibited. 

As you may already know, this shift is about responsible promotion. Therefore, aligning your campaigns with these rules keeps your business compliant while ensuring your message resonates with the right audience. 

New Sales and Distribution Rules

The sale of nicotine products, especially pouches, is now only available in pharmacies and must stay behind the counter. Convenience stores and other general retailers can no longer stock them, ensuring tighter control over access.

This change might seem limiting, but it also provides businesses with a sales channel that prioritizes specific goals and follows strict rules. Partnering with pharmacies can streamline distribution and help you reach your target audience more effectively.

How These Changes Impact Your Business

Adapting to Health Canada’s new rules requires strategic adjustments across various aspects of your business:

  • Manufacturers: Labels and packaging need to be updated to meet the new standards. Additionally, products may need reformulation to comply with flavor restrictions, as only mint and menthol are permitted.
  • Suppliers: Distribution channels must shift to focus on pharmacy sales. This may involve building new partnerships and streamlining supply chains.
  • Marketers: Advertising strategies must be reviewed and refined. Focus on clear, evidence-based messaging that targets adult smokers and highlights approved therapeutic benefits.

While these adjustments may seem challenging at first, they also create opportunities to demonstrate your commitment to safety, compliance, and customer trust.

How to Stay Ahead

Navigating these changes doesn’t have to be overwhelming. Here are actionable steps to ensure compliance:

  1. Understand the rules: Start by reviewing Health Canada’s full guidelines on advertising nicotine replacement therapies.
  2. Update your products: Ensure your labels and packaging clearly display the required nicotine content and health warnings in a way that meets the standards. If necessary, you’ll need to adjust product formulations to meet flavor restrictions.
  3. Revise your marketing: Focus on approved claims, like smoking cessation benefits, and target adult smokers. Avoid any messaging that could appeal to youth or non-smokers.
  4. Optimize your sales strategy: Shift your focus to pharmacy sales and strengthen partnerships with regulated distributors.
  5. Get expert support: Compliance can be complex, but it doesn’t have to be. At Quality Smart Solutions, we specialize in helping businesses meet regulatory requirements quickly and effectively.

The Bottom Line

As you’ve learned, Health Canada’s new nicotine rules are all about creating a safer, more transparent market for consumers. By adapting to these changes, you protect your business, build trust with your audience, and position yourself as a leader in the industry.

Need help with the new rules? Quality Smart Solutions can help you meet NRT compliance. Contact us today and let us guide you through the process!

Categories
Blog

FDA 510(k) Pre-Submission: Steps for Medical Device Approval

Medical diagnostic device with a control panel and digital screen displaying test results, used for optical measurements.Are you trying to make sense of the FDA’s 510(k) pre-submission process? You’re not alone. Many companies, especially those new to the regulatory landscape, find themselves wondering where to start, what’s required, and how to get FDA approval for their medical devices. Without a clear plan, it’s easy to waste time and money on unnecessary steps, or worse, miss critical requirements that delay approval by years. 

That’s where the pre-submission process helps by clarifying what’s needed early on. Connecting with the FDA at this stage can prevent costly mistakes, keep your submission on track, and give you a roadmap for moving forward with confidence.  

By engaging with the FDA early, you’ll gain insights that can help avoid unexpected requirements or delays, setting you up for a smoother journey to approval. Keep reading to learn more about how the pre-submission process works and what steps to follow. 

What is the FDA 510(k) Pre-Submission Process? 

The FDA 510(k) pre-submission process is a chance to open a conversation with the FDA before committing to a full application. It begins by creating a structured document package that explains your device’s technology, intended use, and operation.  

This preparation demonstrates to the FDA that you’ve thoroughly researched your regulatory needs and are ready to proceed with compliance.

The pre-submission process actually helps you build your regulatory strategy by connecting with the FDA early. You’re allowed to ask questions on specific topics, like intended use, regulatory strategy, or software validation, to get clear, actionable feedback that helps you avoid missteps.

And here’s something you might not know: this process is part of the FDA’s Q-Submission Program, which supports several regulatory pathways, including 510(k). Curious to learn more? You can find more details in the FDA’s official guidance on the Q-Submission Program

Key Steps in the FDA 510(k) Pre-Submission Process

Following these steps in the pre-submission process can help you avoid roadblocks and streamline your path to FDA approval. Here are the essential steps to follow in the FDA 510(k) pre-submission process: 

  1. Build your document package 
    To begin, start by putting together a comprehensive package that details your device’s technology, intended use, and comparisons with similar products. This package should reflect your due diligence regarding regulatory requirements and competitive products. 
  2. Ask targeted questions 
    Once your package is ready, you can submit questions on specific topics, such as intended use, regulatory strategy, or validation methods. While you have flexibility, focus on well-chosen questions for the most practical feedback. Clients pay us to ensure their document package is clear and to choose the right questions. FDA responses typically arrive within 60 days, depending on their workload. 
  3. Review FDA responses and follow-up 
    After receiving responses, review the FDA’s feedback carefully. If anything is unclear, schedule a follow-up meeting with FDA specialists to discuss your technology and clarify any points. These one or two-hour meetings are ideal for getting additional insights into questions that may need further discussion.
  4. Reuse pre-submission documents 
    Did you know? One of the biggest advantages is that much of the work done in pre-submission can be reused in your official submission. Documentation developed during pre-submission serves as a foundation for your final 510(k) application, saving time and effort. 

Why the FDA 510(k) Pre-Submission Process Matters

Many companies feel the pressure to get their devices to market as fast as possible, but skipping or rushing through pre-submission can often lead to setbacks. For complex devices, approval timelines can vary widely, sometimes stretching from two years to five years or even longer if unexpected issues arise. Who wants to face delays like that? 

That’s why the pre-submission process is so valuable: it gives you a clear preview of what the FDA expects, helping you avoid surprises and keep your device on a faster, more reliable path to approval.  

The work we do at Quality Smart Solutions in pre-submission isn’t just about getting FDA feedback, it’s also about creating a foundation for a successful, streamlined approval process. By investing in pre-submission, clients set themselves up for a smoother journey through FDA approval, avoiding costly and time-consuming mistakes.

Common Questions in FDA 510(k) Pre-Submission

Here are a few examples of questions that can guide your device approval process: 

  • Is clinical testing required for this device? 
  • What specific performance standards should we meet? 
  • Can we use a particular testing approach, or are alternatives preferred? 

These questions help focus your efforts and make sure you’re on the right path from the start. 

How Quality Smart Solutions Can Help

Navigating the FDA pre-submission process for medical devices doesn’t have to be overwhelming. At Quality Smart Solutions, our consulting team is here to guide each step, from creating your regulatory strategy to building a well-prepared submission package. 

  • Regulatory strategy: We help you find the best path to FDA approval. 
  • Submission package: Our team prepares a clear, complete package that meets FDA standards. 
  • Targeted FDA questions: We guide you in asking the right questions to avoid roadblocks. 
  • Follow-up support: We’re here to guide you through each step with the FDA. 
  • Efficient 510(k) submission: We make sure all your pre-submission work flows right into your final application, saving you time. 

Let us help you bring your device to market with confidence and clarity, every step of the way. 

Categories
Blog

How to Ensure Compliance with Canada’s Infant Formula Registration

Canada Infant Formula Registration Process

Are you looking to bring your infant formula to the Canadian market? Successfully navigating Canada infant formula registration is essential to ensure compliance with Health Canada’s strict regulations.

Canada enforces some of the world’s strictest regulations to ensure that infant formulas meet the highest standards for safety, quality, and nutrition. Successfully navigating this process requires a thorough understanding of Health Canada’s guidelines.

In this guide, we’ll break down the essential steps you need to follow to ensure compliance and streamline your registration. Keep reading to gain insights into the regulatory requirements and best practices for a successful market entry.

Step-by-Step: Canada Infant Formula Registration Process

1. Understand Health Canada’s Regulatory Framework

Before applying, familiarize yourself with Canada’s Food and Drugs Act and Food and Drug Regulations (FDR), which set strict safety and nutrition standards. Key regulatory areas include: 

  • Nutritional composition: Infant formulas must meet strict dietary thresholds for proteins, fats, carbohydrates, vitamins, and minerals. 
  • Labeling requirements: Labels must comply with Health Canada’s detailed guidelines on nutritional claims, ingredient lists, and preparation instructions. 
  • Pre-market notification (PMN): Companies must submit a PMN detailing the formula’s composition, manufacturing process, and safety before selling in Canada. 

2. Submit a Comprehensive Pre-Market Notification (PMN)

A well-prepared PMN is critical for approval. Ensure you include: 

  • Nutritional analysis: Provide detailed nutrient data that meets Health Canada’s guidelines. 
  • Safety and efficacy data: Submit clinical trial data or other safety reports verifying compliance. 
  • Manufacturing process overview: Detail ingredient sourcing, production quality controls, and contamination prevention measures. 

3. Conduct Clinical Studies (If Required)

For novel or significantly altered formulas, Health Canada may require clinical studies. These studies must follow Good Clinical Practices (GCP) and confirm the formula’s safety and ability to support infant growth and development. 

4. Comply with Labeling Regulations

Labeling plays a crucial role in compliance. Your infant formula’s label must clearly present: 

  • Complete Nutritional Information: A detailed breakdown of essential nutrients. 
  • Approved Health Claims: Only permitted claims regarding nutritional adequacy can be included. 
  • Preparation Instructions: Clear guidelines for safe preparation and feeding. 

5. Submit Your Application to Health Canada

Once your documentation is ready, submit your PMN via the Electronic Regulatory Submissions (ERS) Gateway. Accuracy is crucial to avoid delays. 

  • Typical Review Time: 90-180 days. Missing information can result in further delays, so ensure all details are correct. 

6. Maintain Ongoing Compliance Monitoring

Compliance does not end after registration. Companies must continue to meet Health Canada’s evolving standards by: 

  • Adverse Event Reporting: Promptly report any safety concerns. 
  • Product Recalls: Implement immediate recall procedures if necessary. 
  • Label Updates: Adjust labeling to reflect any regulatory changes. 

Common Questions About Infant Formula Registration 

How long does the approval process take? 

The approval process for infant formula registration in Canada typically takes between 90 and 180 days. The timeline depends on the completeness of the submission and whether additional information is required by Health Canada. 

Do all formulas require clinical studies? 

Not all infant formulas require clinical studies. However, if a formula is new or significantly modified, Health Canada may mandate clinical trials to confirm its safety and effectiveness. 

Can I make health claims on my infant formula label? 

Yes, but only those that have been approved by Health Canada. Ensuring compliance with these regulations is essential to avoid delays and potential penalties. 

Why Compliance Matters: Avoiding Costly Mistakes 

Failing to meet Health Canada’s requirements can lead to: 

  • Delays in market entry due to missing or incorrect documentation. 
  • Increased costs from additional clinical trials and resubmissions. 
  • Regulatory penalties for non-compliant labeling or safety violations. 

How Quality Smart Solutions Can Help 

Navigating Canada’s infant formula registration process can be complex. Quality Smart Solutions offers expert guidance to streamline your application and ensure compliance. Our regulatory specialists will help you prepare accurate submissions, reducing the risk of costly delays or rejections. 

Need assistance with your infant formula registration? Fill out the form below or contact us to ask us any questions you have.   

Categories
News

Health Canada Opens 75-Day Consultation on Batch 4b – Share Your Input

FDA Warning Letter

Health Canada Opens 75-Day Consultation on Batch 4b – Share Your Input

The Natural and Non-Prescription Health Products Directorate (NNHPD) invites industry stakeholders to provide feedback on Batch 4b, with consultation open for 75 days. We encourage you to support any suggestions for monograph revisions with published evidence or clear rationale.

What’s Included in Batch 4b?

  • Updated Monographs for Topical Ingredients
    • 16 single-ingredient monographs for traditional plants now represent ingredient quantities as percentages. Your input confirms whether these concentrations are reasonable and align with industry standards.
  • New Topical Analgesics/Antipruritic Monograph
    • This addition, featuring natural health product ingredients, is based on the Nonprescription Drug Topical Anaesthetic/Analgesic/Antipruritic Labelling Standard.

Access all documents in Batch 4b, including new monographs, directly here.

Step-by-Step Instructions to Submit Comments

Follow these steps to access and comment on the documents:

  1. Choose Your Language
    • Double-click the language-specific folder.
  2. Download the Monograph
    • Double-click the monograph you wish to view and click “Download” in the top right corner.
  3. Enable Editing
    • Open the document on your computer and click “Enable Editing” if prompted by a Protected View banner.
  4. Add Comments
    • Go to the “Review” tab in Word and use “New Comment” to add your input.
  5. Send Back Your Edited Document
    • Save your version with comments and email it to: nnhpd.consultation-dpsnso@hc-sc.gc.ca

Prefer Text-Based Comments?
You can also email your comments directly, clearly linking each comment to the corresponding monograph.

Deadline for Submission: January 14, 2025

We appreciate your insights and participation in shaping health product standards. Feedback must be submitted by January 14, 2025.

How Quality Smart Solutions Can Assist

Quality Smart Solutions specializes in guiding businesses through regulatory challenges like this consultation. Our experts clarify the comment submission process, ensuring your insights are aligned with regulatory expectations—partner with us to make your voice heard in compliance consultations like Batch 4b. Reach out to us by filling out the form below.

Categories
Blog

How to Master FDA Audits for Your Dietary Supplement Facility: A Complete Preparation Guide

Introduction 

Preparing for an FDA audit can be challenging, especially for dietary supplement manufacturers who must meet stringent Good Manufacturing Practices (GMP) requirements. The FDA regularly inspects dietary supplement facilities to ensure manufacturing, labeling, and safety regulations compliance. But how can you ensure you’re ready? Failing to meet FDA standards can lead to severe consequences, including costly recalls and facility shutdowns. This guide will outline practical strategies to help you confidently and efficiently navigate the FDA audit process. 

What is an FDA Audit and Why is it Essential? 

An FDA audit is a thorough review of your manufacturing facility, focusing on processes, practices, and documentation to verify compliance with the FDA’s Current Good Manufacturing Practices (cGMP). The FDA’s primary concerns during an audit include: 

  • Ensuring safe manufacturing practices. 
  • Validating that product labeling is accurate and non-misleading. 
  • Confirming adherence to testing standards. 

Why Does It Matter? 

Failing an FDA audit could damage your brand’s reputation, disrupt your supply chain, and, in extreme cases, halt operations entirely. Ensuring your facility is always ready for inspection can minimize risk, safeguard your business, and build consumer trust. 

How to Prepare for an FDA Audit: Step-by-Step Guidelines 

1. Review and Update Your SOPs Regularly 

Ensure your Standard Operating Procedures (SOPs) are thorough, up-to-date, and reflect daily operations accurately. SOPs are crucial for: 

a. Detailing manufacturing processes. 

b. Outlining quality control protocols. 

c. Documenting employee training and qualifications. 

d. Ensuring traceability of raw materials. 

Action: Appoint a dedicated team to review SOPs regularly and ensure employees understand these protocols inside and out. 

2. Conduct Routine Internal Audits 

Internal audits allow you to identify issues before an official inspection. Prioritize areas such as: 

a. Documentation accuracy. 

b. Maintenance logs for equipment. 

c. Sanitation and cleanliness. 

d. Traceability of ingredients and products. 

Action: Schedule quarterly internal audits to address any potential gaps in compliance. Use these audits as practice to refine your processes for the real audit. 

3. Invest in Comprehensive Employee Training 

The FDA assesses employee training quality, as untrained staff can contribute to errors in manufacturing, packaging, and documentation. 

Action: Develop a training program that includes onboarding and ongoing education for all staff. Keep detailed training records to demonstrate competency and compliance readiness. 

4. Ensure Accurate, Detailed Record-Keeping 

Record-keeping is crucial for FDA audits, covering areas like: 

a. Batch production records. 

b. Results of quality control tests. 

c. Supplier qualification documents. 

d. Product labeling approvals. 

Action: Implement a structured system to ensure all records are up-to-date, complete, and readily accessible. Automating this process reduces the risk of errors and ensures records are audit-ready. 

5. Enhance Product Testing and Quality Control 

Dietary supplements require rigorous quality control to guarantee product safety including: 

a. Testing raw materials and finished products for contaminants. 

b. Keeping records of all testing for each batch. 

c. Ensuring validated testing methods. 

Action: Partner with a reliable third-party lab to conduct product testing and ensure your protocols meet FDA standards. Organize testing records for easy access during inspections. 

6. Verify Your Product Labeling and Claims 

The FDA scrutinizes dietary supplement labels to verify compliance with regulatory guidelines. Misleading or exaggerated claims can lead to penalties. 

Action: Review all product labels to ensure they align with FDA regulations. Avoid claims suggesting your product treats, cures, or prevents diseases, as these could reclassify the supplement as a drug. 

7. Schedule Mock Audits for Stress-Free Preparation 

Mock audits simulate the inspection process, allowing you to identify weaknesses and make improvements. 

Action: Hire a third-party consultant to conduct a mock FDA audit. This external perspective provides invaluable insights and allows you to fine-tune operations before the actual audit. 

Frequently Asked Questions (FAQs) 

  1. How frequently does the FDA audit dietary supplement facilities?

Typically, the FDA audits facilities every 2-3 years, but high-risk or more extensive facilities may see more frequent inspections. 

  1. What if my facility fails an FDA audit?

A failed audit can result in warning letters, product recalls, or even legal action. Fortunately, manufacturers often have an opportunity to address deficiencies before facing penalties. 

  1. How long does an FDA audit usually last?

Audits can last from a few days to several weeks, depending on the facility’s complexity and size. 

Conclusion 

Preparing for an FDA audit doesn’t have to be stressful. You can ensure your facility is always audit-ready by following these steps—regular SOP reviews, internal audits, staff training, accurate record-keeping, thorough testing, compliant labeling, and mock audits. Staying proactive and addressing any issues early will strengthen your compliance and help you confidently face FDA inspections. 

How Quality Smart Solutions Can Help 

At Quality Smart Solutions, we specialize in comprehensive FDA audit preparation for dietary supplement manufacturers. Our expert team offers services ranging from SOP development and employee training to mock audits, helping you achieve compliance with ease. Trust us to guide you through every step of the audit process so you’re fully prepared to meet FDA standards and build lasting consumer confidence. 

Categories
Blog

Health Canada’s NDS, SNDS, and ANDS Pathways: Which One Is Right for You?

If you’re thinking about bringing a pharmaceutical product to the Canadian market, getting familiar with drug submission pathways is a crucial first step. These regulatory routes can seem a bit confusing at first, but understanding them will save you time, money, and potential setbacks. Whether you’re introducing a new drug, modifying an existing one, or entering the generic market, Health Canada requires that you follow a specific regulatory route.

Each submission type (NDS, SNDS, or ANDS) has its own criteria, data requirements, review timelines, and costs. Choosing the wrong one can slow your approval process, increase expenses, or even result in rejection. But don’t worry, this blog will walk you through each pathway clearly and simply.

Keep reading to learn which submission pathway best fits your product, and how to avoid common regulatory missteps.

What is an NDS?

A New Drug Submission (NDS) is required for drugs with new active ingredients, formulations, or therapeutic uses that haven’t yet been authorized in Canada. This is the most comprehensive submission type and applies to innovative therapies entering the market for the first time.

When to use NDS

  • Introducing a new active ingredient
  • Launching a drug with a new indication
  • Creating a new dosage form or formulation

Key requirements

  • Extensive clinical and preclinical data
  • Health Canada review time of 300 to 600 days
  • CAD 590,346 submission fee

Example: You’ve developed a new treatment for a chronic condition. Since it’s never been marketed in Canada, you’ll need an NDS to apply.

What is an SNDS?

The Supplemental New Drug Submission (SNDS) is used for significant changes to a drug that has already been approved. If those updates could affect the product’s safety, effectiveness, or quality, you must submit supporting documentation for Health Canada’s review.

When to use SNDS

  • Changing dosage or formulation
  • Adding a new therapeutic use
  • Modifying manufacturing or labelling details

Key requirements

  • Supporting clinical data (as needed)
  • Review time of 180 to 300 days
  • CAD 305,690 submission fee

Example: You want to add a secondary indication for your approved blood pressure medication. This requires an SNDS.

What is an ANDS?

The Abbreviated New Drug Submission (ANDS) is for generic drugs. It allows manufacturers to show that their product is bioequivalent to an approved reference drug, without having to conduct new clinical trials.

When to use ANDS

  • Launching a generic version of a brand-name drug
  • Demonstrating equivalence in absorption and delivery

Key requirements

  • Bioequivalence studies
  • Review time of 180 to 300 days
  • CAD 305,690 submission fee

Example: You’re creating a generic cholesterol-lowering drug. You’ll file an ANDS to show it matches the reference product.

Comparing NDS, SNDS, and ANDS pathways

Now that we’ve gone through each submission pathway, let’s look at them side by side in the comparison chart below. The visual summary below helps clarify how the three options differ in scope, requirements, and timelines. Whether you’re launching a new drug, modifying an approved one, or developing a generic, the chart makes it easier to spot the best fit for your product.

How to navigate Health Canada's drug submission pathways: comparison chartFrequently asked questions

Still unsure which path is right for your product? You’re not alone. Here are some common questions we hear from businesses trying to figure out Health Canada’s drug submission process. We’ve expanded the answers to help you understand what to expect and make informed decisions.

  1. I’m reformulating a drug. Which pathway do I use?
    If the changes affect the product’s safety, quality, or intended use, you’ll need to go through the SNDS process. This includes updates to dosage forms, manufacturing methods, new therapeutic indications, or significant labelling changes.
  2. How long does the ANDS process take?
    It usually takes between 180 and 300 days. That said, a complete and accurate submission can prevent delays. Make sure your bioequivalence studies and supporting documents are in order.
  3. Can I use the NDS pathway for a generic?
    No. Generics must follow the ANDS route. You’ll need to demonstrate that your product is bioequivalent to an approved reference drug, without having to submit new clinical trial data.
  4. Do I need clinical trial data for an SNDS?
    It depends on the nature of the change. If you’re changing the dosage or therapeutic indication, you may need to include new clinical data. For more minor changes, such as manufacturing site updates, this might not be required.
  5. What if my product falls between two categories?
    If your submission doesn’t clearly meet the requirements for one pathway, it’s best to consult Health Canada or work with a regulatory expert. Submitting under the wrong pathway can lead to unnecessary delays or rejections.

How regulatory experts can help

Navigating drug submission pathways doesn’t have to be stressful. Our regulatory team at Quality Smart Solutions can help you evaluate your product, prepare the necessary documentation, and ensure your submission meets Health Canada’s expectations.

Whether you’re preparing an NDS, SNDS, or ANDS, we’ll guide you from strategy through to approval. You can visit our Contact page or simply fill out the form below to schedule a free consultation with one of our regulatory experts.

References

Health Canada. (2024). Fees for the Examination of Drug Submissions and Applications. Government of Canada. Retrieved from https://www.canada.ca/en/health-canada/services/drug-health-product-review-approval/submission-applications/fees.html 

Canada Gazette, Part 1, Volume 158, Number 13. (2024). Notice amending Health Canada’s National Dosimetry Services Products, Services, and Fees Schedule. Government of Canada. Retrieved from https://gazette.gc.ca/rp-pr/p1/2024/2024-03-28/html/notice-avis-eng.html

Health Canada. (2023). Drug Submission Application Review Fees. Government of Canada. Retrieved from https://www.canada.ca/en/health-canada/services/submission-applications/review-fees.html

Subscribe to global regulatory updates

We use cookies to display personalized content, analyze site traffic, provide recommendations, and ensure you have a great browsing experience. By continuing to use our site, you consent to our use of cookies. Privacy Policy.